48TH FLOOR, CHEUNG KONG CENTER, HONG KONG, K3
HUTCHMED Reports ORPATHYS® Plus TAGRISSO® Improves Survival in Lung Cancer
Material disclosure
Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
To Announce 2026 Half-Year Financial Results
Blocklisting Six Monthly Return
Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
Block Admission Application
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis